A Public Option for Clinical Trials? Lessons from Convalescent Plasma
Abstract
The case of clinical trials for convalescent plasma during COVID-19 illustrates important lessons for realizing public sector approaches to biomedical research and development. These lessons, centering on mission, transparency, and spillover effects, can be translated to wider efforts to develop a “public option” for clinical trials.
Link to resource: https://doi.org/10.1017/jme.2024.57
Type of resources: Reading
Education level(s): College / Upper Division (Undergraduates), Graduate / Professional
Primary user(s): Student, Teacher
Subject area(s): Law, Life Science
Language(s): English
Help us improve the FORRT website
We would be grateful if you could complete this survey.
Your feedback will directly inform improvements to navigation, accessibility, and content structure.
Note:All answers are anonymous and will help us make the website better for everyone!